NCT01243476 Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome Status COMPLETED Phase PHASE3
NCT01239797 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Status COMPLETED Phase PHASE3
NCT01222754 Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas Status COMPLETED Phase PHASE1
NCT01222195 Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS) Status TERMINATED Phase PHASE2
NCT01218555 Study of Everolimus (RAD001) in Combination With Lenalidomide Status COMPLETED Phase PHASE1
NCT01217957 A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Status COMPLETED Phase PHASE1/PHASE2
NCT01216683 Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Status COMPLETED Phase PHASE2
NCT01215344 First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Status COMPLETED Phase PHASE2
NCT01208662 Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT01208051 Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT01207921 Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma Status COMPLETED Phase PHASE1
NCT01200004 Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide Status TERMINATED Phase PHASE1
NCT01197560 Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Status COMPLETED Phase PHASE2/PHASE3
NCT01194791 Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed Status COMPLETED Phase PHASE2
NCT01183663 Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) Status COMPLETED Phase PHASE1
NCT01180569 Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma Status WITHDRAWN Phase PHASE1/PHASE2
NCT01169337 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT01169298 A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma Status COMPLETED Phase PHASE1
NCT01166035 Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors Status UNKNOWN Phase PHASE1/PHASE2